Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis [PDF]
Cristiano Pagnini +8 more
openalex +1 more source
Formulation and Evaluation of Mesalamine Nanosphere Tablet
Tejas S. Pachpute +3 more
openalex +2 more sources
Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial [PDF]
Stephen B. Hanauer +6 more
openalex +1 more source
Early and sustained efficacy of delayed-release oral Mesalamine in moderately active ulcerative Colitis patients: Combined results from the ASCEND I, II, & III trials [PDF]
G Lichtenstein, D Ramsey, E Loftus
openalex +1 more source
Box-Behnken experimental design in the development of pectin-compritol ATO 888 compression coated colon targeted drug delivery of mesalamine [PDF]
Nirav Patel +2 more
openalex +1 more source
Diagnostic Challenges and Management of Crohn's Disease: The Value of Capsule Endoscopy. [PDF]
Alexander S +3 more
europepmc +1 more source

